Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Research & Development (2016 - 2025)

Catalyst Pharmaceuticals' Research & Development history spans 16 years, with the latest figure at $1.8 million for Q4 2025.

  • For Q4 2025, Research & Development fell 52.42% year-over-year to $1.8 million; the TTM value through Dec 2025 reached $12.7 million, changed 0.48%, while the annual FY2025 figure was $12.7 million, 0.48% changed from the prior year.
  • Research & Development reached $1.8 million in Q4 2025 per CPRX's latest filing, down from $2.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $83.7 million in Q3 2023 to a low of $1.8 million in Q4 2025.
  • Average Research & Development over 5 years is $7.8 million, with a median of $3.8 million recorded in 2024.
  • Peak YoY movement for Research & Development: soared 906.76% in 2023, then crashed 96.07% in 2024.
  • A 5-year view of Research & Development shows it stood at $5.0 million in 2021, then fell by 18.01% to $4.1 million in 2022, then tumbled by 51.82% to $2.0 million in 2023, then skyrocketed by 92.6% to $3.8 million in 2024, then plummeted by 52.42% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Research & Development are $1.8 million (Q4 2025), $2.7 million (Q3 2025), and $4.4 million (Q2 2025).